Held May 13-16 tadalis-sx.net.

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR Argos Therapeutics today announced the presentation of data from the Stage 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and in addition outcomes in substantially increased time to viral rebound in HIV sufferers treated with AGS-004 following antiretroviral therapy interruption. The data were discussed in an oral display at the 19th Annual Canadian Conference on HIV/AIDS Research , held May 13-16, 2010 in Saskatoon, Saskatchewan tadalis-sx.net .